Advanced search
Publication Cover
Leukemia & Lymphoma Volume 55, 2014 - Issue 3
Submit an article Journal homepage
734
Views
66
CrossRef citations to date
0
Altmetric
Research Article

Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease

Jacob D. SoumeraiCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA;Harvard Medical School, Boston, MA, USA
,
Matthew D. HellmannCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA;Harvard Medical School, Boston, MA, USA
,
Yang FengDepartment of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA
,
Aliyah R. SohaniHarvard Medical School, Boston, MA, USA;Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
,
Christiana E. ToomeyCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA
,
Jeffrey A. BarnesCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA;Harvard Medical School, Boston, MA, USA
,
Ronald W. TakvorianCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA;Harvard Medical School, Boston, MA, USA
,
Donna NeubergDepartment of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA
,
Ephraim P. HochbergCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA;Harvard Medical School, Boston, MA, USA
&
Jeremy S. AbramsonCenter for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA, USA;Harvard Medical School, Boston, MA, USACorrespondence[email protected]
 show all
Pages 538-543 | Received 19 Mar 2013, Accepted 29 May 2013, Published online: 29 Jul 2013

References

  • Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780–2795.
  • Gaulard P, Harris NL, Pileri SA, et al. Primary mediastinal (thymic) large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of hematopoietic and lymphoid tissues. 4th ed. Lyon: WHO; 2008. pp. 250–251.
  • Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
  • Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
  • Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
  • Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
  • Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011;22:664–670.
  • Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006;17:123–130.
  • Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist 2012;17:239–249.
  • Savage KJ, Yenson PR, Shenkier T, et al. The outcome of primary mediastinal Large B-cell lymphoma (PMBCL) in the R-CHOP treatment era. Blood 2012;120(Suppl. 1): Abstract 303.
  • Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004;90:372–376.
  • Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002;87:1258–1264.
  • Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to1999. Br J Haematol2005;130:691–699.
  • Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 1997;15:1646–1653.
  • Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97:1428–1437.
  • Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878–1886.
  • Straus DJ. Long-term survivorship at a price: late-term, therapy-associated toxicities in the adult hodgkin lymphoma patient. Ther Adv Hematol 2011;2:111–119.
  • Witzens-Harig M, Ho AD, Kuhnt E, et al. Primary mediastinal B cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: 5-year results of the Mabthera International Trial Group (MInT) Study. Blood 2012;120(Suppl. 1): Abstract 1612.
  • Faris JE, LaCasce AS. Primary mediastinal large B-cell lymphoma. Clin Adv Hematol Oncol 2009;7:125–133.
  • Abou-Elella AA, Weisenburger DD, Vose JM, et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. J Clin Oncol 1999;17:784–790.
  • Kirn D, Mauch P, Shaffer K, et al. Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol 1993;11:1336–1343.
  • Bishop PC, Wilson WH, Pearson D, et al. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 1999;17:2479–2485.
  • Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013;368:1408–1416.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.